ຄົ້ນພົບວິທະຍາສາດທີ່ຢູ່ເບື້ອງຫຼັງການປິ່ນປົວການປິ່ນປົວດ້ວຍ CAR T Cell ໃນປະເທດອິນເດຍ! ສຳຫຼວດເບິ່ງວິທີການປິ່ນປົວແບບປະຕິວັດນີ້ປ່ຽນຈຸລັງພູມຄຸ້ມກັນຂອງເຈົ້າໃຫ້ເປັນຜູ້ຕໍ່ສູ້ກັບມະເຮັງ. ອ່ານ blog ຂອງພວກເຮົາໃນປັດຈຸບັນເພື່ອຮຽນຮູ້ເພີ່ມເຕີມກ່ຽວກັບການປິ່ນປົວມະຫັດສະຈັນນີ້ແລະວິທີການ..
ເຈົ້າເຄີຍສົງໄສບໍ່ວ່າມີວິທີທີ່ມີປະສິດທິພາບໃນການຕໍ່ສູ້ກັບມະເຮັງບໍ? ດຽວນີ້ລອງນຶກພາບເບິ່ງວ່າ ມື້ໃດມື້ໜຶ່ງເຈົ້າໄດ້ພົບແສງແຫ່ງຄວາມຫວັງໃນການຕໍ່ສູ້ຕ້ານມະເຮັງ, ການປິ່ນປົວທີ່ໃຊ້ພະລັງຂອງລະບົບພູມຄຸ້ມກັນຂອງຮ່າງກາຍຂອງເຈົ້າເພື່ອແນໃສ່ເປົ້າໝາຍ..
Dec 2022: Olutasidenib (Rezlidhia) capsules were approved by the Food and Drug Administration (FDA) for adult patients with relapsed or resistant acute myeloid leukaemia (AML) who have a susceptible IDH1 mutation as identifie..
Dec 2022: A new Monday-Wednesday-Friday dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn has been approved by the Food and Drug Administration (Rylaze, Jazz Pharmaceuticals). Patients should receive 25 mg/m..
June 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older with..
June 2022: The FDA has approved the drug azacitidine (Vidaza, Celgene Corp.) for children with newly diagnosed juvenile myelomonocytic leukaemia (JMML).The pharmacokinetics, pharmacodynamics, safety, and activity of azacitidine p..
Leukemia in childhood Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). Chronic leu..
ເດືອນມີນາ 2022: ອົງການອາຫານ ແລະຢາໄດ້ອະນຸມັດຢາ rituximab (Rituxan, Genentech, Inc.) ໂດຍສົມທົບກັບການປິ່ນປົວດ້ວຍທາງເຄມີສໍາລັບ CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma..
ພະຈິກ 2021: Asciminib (Scemblix, Novartis AG) ໄດ້ຮັບການອະນຸມັດຢ່າງເລັ່ງດ່ວນໂດຍອົງການອາຫານ ແລະຢາສຳລັບຄົນເຈັບທີ່ເປັນໂຣກມະເຮັງຕັບອັກເສບ Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) ໃນໄລຍະຊໍາເຮື້ອ (CP) ຜູ້ທີ່ມີ pr..
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). In..